Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer

NCT00006034 is registered in ClinicalTrials.gov with Intracel as lead sponsor.

NCT NCT00006034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00006034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multicenter Phase III Trial Evaluating the Efficacy and Safety of BCI-ImmuneActivator Versus Adriamycin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer
Lead sponsor
Intracel
Phase
Phase 3
Overall status
Completed
Start date
June 30, 1998
Completion date
March 31, 2004
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer